https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22272 2=96% and 88% respectively). Meanwhile, statin was more effective than placebo in reducing LDL (WMD=− 0.87, 95%CI  − 1.18~ − 0.55, P<0.0001), TC (WMD=− 1.23 95%CI  − 1.35~ − 1.11, P<0.00001), TG (WMD= − 0.50, 95%CI  − 0.73~ − 0.27, P<0.00001); and statin + metformin was more effective than metformin in lowering LDL (WMD= − 0.84, 95%CI:  − 1.33~ − 0.354, P=0.0009), TC (WMD= − 1.28, 95%CI: − 1.47~ − 1.10, P<0.00001), and TG (WMD= − 0.27, 95%CI:  − 0.36~ − 0.19, P<0.00001). Heterogeneities were detected during the meta-analysis.]]> Wed 24 Jun 2020 17:48:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38395 146.7 ng/ml). The s-IGF-I level was not associated with recurrent stroke (N=79) or death (N=44), although it correlated with recovery (r=0.12, P=0.035). In the regression analysis, s-IGF-I associated with recovery between 3 months and 7 years (but not between 2 and 7 years). The associations did not withstand adjustment for age and sex. For comparison, the corresponding associations between 3 months and 2 years withstood all adjustments. Conclusion: The association for s-IGF-I with long-term post-stroke recovery persists after 7 years, which is also reflected in the mRS score distributions at all time-points. The effects are however modest, and not driven by mortality or recurrent stroke.]]> Mon 29 Jan 2024 17:47:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19889 Fri 14 Aug 2015 17:45:16 AEST ]]>